

**In the Claims:**

The current status of all claims is listed below and supersedes all previous lists of claims.


Please cancel claims 1-9, 14, 19, and 30 without prejudice to their presentation in another application, and amend claims 26-30 as follows:

1-20. (canceled).

21. (previously presented) A compound which is  
( $\pm$ )-7-methyl-2-morpholin-4-yl-9-(l-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one,  
( $\pm$ )-2-(l-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl)  
amino)benzoic acid,  
( $\pm$ )-2-(l-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-  
yl]ethyl}amino)benzonitrile,  
( $\pm$ ) methyl 2-(l-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-  
yl]ethyl}amino)benzoate, or  
( $\pm$ )-7-methyl-2-(morpholin-4-yl)-9-(l-{{2-(2H-tetrazol-5-yl)phenyl}amino} ethyl)-  
pyrido[1,2-a]pyrimid-4-one.

22-25. (canceled).

26. (currently amended) A compound according to formula (I):



wherein [ , ] :

R is H, C<sub>1</sub>-C<sub>6</sub> branched or straight chain alkyl, [[or]] aryl<sub>1</sub> or (CH<sub>2</sub>)<sub>n</sub>-aryl;

R<sub>1</sub> is H, OH, OCH<sub>3</sub>, OCF<sub>3</sub>, F, Cl, CF<sub>3</sub>, C<sub>1</sub>-C<sub>6</sub> branched or straight chain alkyl, [[or]] aryl<sub>1</sub> or (CH<sub>2</sub>)<sub>n</sub>-aryl;

R<sub>2</sub> is C<sub>1</sub>-C<sub>6</sub> branched or straight chain alkyl, [[or]] aryl<sub>1</sub> or (CH<sub>2</sub>)<sub>n</sub>-aryl in either the R or the S configuration;

R<sub>3</sub> is one or more of H, F, Cl, Br, I, CN, CO<sub>2</sub>H, CO<sub>2</sub>R, NO<sub>2</sub>, CF<sub>3</sub>, substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub> alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, OCH<sub>3</sub>, OCH<sub>2</sub>F, OCHF<sub>2</sub>, OCF<sub>3</sub>, OR, OSO<sub>2</sub>-aryl, substituted or unsubstituted amine, NHCOR, NHSO<sub>2</sub>R, CONHR, or SO<sub>2</sub>NHR<sub>1</sub>


X is C or N<sub>1</sub> and

Y is N or O.

27. (currently amended) A method for inhibiting phosphoinositide 3-kinase, preventing or treating cardiovascular disease, preventing or treating respiratory disease, preventing or treating cancer, or preventing or treating disease linked to disordered white blood cell function;

comprising administering an effective amount of any one of the compounds a compound of claim 26 to a patient in need thereof.

28. (currently amended) The A method of claim 27, treating cardiovascular disease comprising administering the 2-morpholino-substituted derivative of formula (I) wherein:



R is H, C<sub>1</sub>-C<sub>6</sub> branched or straight chain alkyl or aryl;

R<sub>1</sub> is H, OH, OCH<sub>3</sub>, OCF<sub>3</sub>, F, Cl, CF<sub>3</sub>, or C<sub>1</sub>-C<sub>6</sub> branched or straight chain alkyl;

R<sub>2</sub> is C<sub>1</sub>-C<sub>6</sub> branched or straight chain alkyl, or aryl in either the R or the S configuration;

R<sub>3</sub> is one or more of H, F, Cl, Br, CN, CO<sub>2</sub>H, CO<sub>2</sub>R, NO<sub>2</sub>, CF<sub>3</sub>, branched or straight chain C<sub>1</sub>-C<sub>6</sub> alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, OCH<sub>3</sub>, OCH<sub>2</sub>F, OCHF<sub>2</sub>, OCF<sub>3</sub>, OR, substituted or unsubstituted amine, NHCOR, NHSO<sub>2</sub>R, CONHR, or SO<sub>2</sub>NHR;

X is C or N; and

Y is N or O.

29. (currently amended) The method of claim 27, wherein the inhibitor administered is selected from the group consisting of:

( $\pm$ )-7-methyl-9-{[methyl(phenyl)amino]methyl}-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-195);

( $\pm$ )-7-methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one (TGX-221);

( $\pm$ )-7-methyl-2-morpholin-4-yl-9-[1-(4-fluorophenylamino)ethyl]-pyrido[1,2-a]pyrimidin-4-one (TGX-224);

( $\pm$ )-9-[1-(3,4-difluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-237);

( $\pm$ )-9-[1-(2,5-difluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-238);

( $\pm$ )-9-[1-(3,5-difluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-239);

( $\pm$ )-9-[1-(4-fluoro-2-methylphenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-240);

( $\pm$ )-9-[1-(4-chlorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-243);

( $\pm$ )-9-[1-(3,4-dichlorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-244);

( $\pm$ )-9-[1-(3fluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-247);

( $\pm$ )-9-[1-(3-chlorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-248);

( $\pm$ ) 7-methyl-2-morpholin-4-yl-9-[1-(2-thiazolylamino)ethyl]-pyrido[1,2-a]pyrimidin-4-one (TGX-261);

( $\pm$ )-7-methyl-9-[1-(3-methylphenylamino)ethyl]-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-262);

( $\pm$ )-7-methyl-2-morpholin-4-yl-9-[1-(3-trifluoromethylphenylamino)ethyl]-pyrido[1,2-a]pyrimidin-4-one (TGX-264); [[and]]

( $\pm$ )-7-methyl-2-morpholin-4-yl-9-[1-(2-pyridinylamino)ethyl]-pyrido[1,2-a]pyrimidin-4-one (TGX-295)[[.]] ;

( $\pm$ )-2-( $\{$ 1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl $\}$  amino)benzoic acid (KN-309);

( $\pm$ ) methyl 2-( $\{$ 1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl $\}$  amino)benzoate (KN-321);

( $\pm$ ) 2-( $\{$ 1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl $\}$  amino)benzonitrile (KN-320);

( $\pm$ )-2-( $\{$ 1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl $\}$  amino)benzonitrile (KN-320);

( $\pm$ )-7-methyl-2-(morpholin-4-yl)-9-(1- $\{$ [2-(2H-tetrazol-5-yl)phenyl] amino $\}$  ethyl)-pyrido[1,2-a]pyrimidin-4-one (KN-325); and

( $\pm$ )-2-(4-morpholinyl)-8-[1-(phenylamino)ethyl]-4H-1-benzopyran-4-one (TGX-280).

30. (canceled).